Placeholder Banner

BIO to redouble efforts to ensure regulatory decision-making is "grounded in scientific and medical expertise"

April 21, 2023
Media Contact

The Supreme Court ruled today that mifepristone will remain accessible during the appeals process of the April 7 Texas ruling that would have declared the Food and Drug Administration (FDA) approval of the drug invalid. 

BIO interim President and CEO, Rachel King, made the following statement: 

“Today’s decision is an important development for patients and for ensuring access to approved medicines. However, we must redouble our efforts to preserve and protect the FDA’s long-standing role as the authority in determining the safety and efficacy of medicines. As legal and medical experts have noted, the courts do not have the expertise or medical training to make these types of complex scientific determinations. At BIO, we will continue to organize and mobilize on behalf of patients and will work tirelessly to ensure that regulatory decision-making is grounded in scientific and medical expertise.”




Discover More
The following statement concerning the Environmental Protection Agency’s final rule on regulation of Plant Incorporated Protectants (PIPs) under the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA) may be attributed to John Murphy, chief…
BIO CEO Rachel King and Califf will discuss  issues impacting FDA and the biotech community WASHINGTON - (May 25, 2023) – Robert Califf, commissioner of the Food and Drug Administration, will be the keynote speaker on day three of the 2023 BIO…
BIO CEO Rachel King and Couric to Discuss How Standing Up for Science and Patients Are at the Heart of Biotech WASHINGTON - (May 16, 2023) – Katie Couric, award-winning journalist, New York Times best-selling author, and longtime cancer…